JP2012527467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012527467A5 JP2012527467A5 JP2012511971A JP2012511971A JP2012527467A5 JP 2012527467 A5 JP2012527467 A5 JP 2012527467A5 JP 2012511971 A JP2012511971 A JP 2012511971A JP 2012511971 A JP2012511971 A JP 2012511971A JP 2012527467 A5 JP2012527467 A5 JP 2012527467A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- alkynyl
- alkenyl
- carbocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 137
- 150000001875 compounds Chemical class 0.000 claims 42
- 125000003118 aryl group Chemical group 0.000 claims 41
- 125000004452 carbocyclyl group Chemical group 0.000 claims 32
- 125000000623 heterocyclic group Chemical group 0.000 claims 32
- 125000000304 alkynyl group Chemical group 0.000 claims 26
- -1 bromo, chloro, iodo Chemical group 0.000 claims 26
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 20
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- 208000002193 Pain Diseases 0.000 claims 16
- 125000003342 alkenyl group Chemical group 0.000 claims 16
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 7
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 claims 2
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 claims 2
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010011796 Cystitis interstitial Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028836 Neck pain Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 230000005796 circulatory shock Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 0 *C(C=CC1)=CC=C1[C@@](C1)ON=C1OC1C=CC(C(O)=O)=NC1 Chemical compound *C(C=CC1)=CC=C1[C@@](C1)ON=C1OC1C=CC(C(O)=O)=NC1 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17928309P | 2009-05-18 | 2009-05-18 | |
| US17928509P | 2009-05-18 | 2009-05-18 | |
| US17928009P | 2009-05-18 | 2009-05-18 | |
| US61/179,285 | 2009-05-18 | ||
| US61/179,280 | 2009-05-18 | ||
| US61/179,283 | 2009-05-18 | ||
| PCT/US2010/035309 WO2010135360A1 (en) | 2009-05-18 | 2010-05-18 | Isoxazolines as inhibitors of fatty acid amide hydrolase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012527467A JP2012527467A (ja) | 2012-11-08 |
| JP2012527467A5 true JP2012527467A5 (enExample) | 2013-07-04 |
Family
ID=43126477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511971A Ceased JP2012527467A (ja) | 2009-05-18 | 2010-05-18 | 脂肪酸アミドヒドロラーゼ阻害薬としてのイソオキサゾリン |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP2432771A4 (enExample) |
| JP (1) | JP2012527467A (enExample) |
| KR (1) | KR20120042766A (enExample) |
| CN (1) | CN102459202B (enExample) |
| AR (1) | AR076687A1 (enExample) |
| AU (1) | AU2010249674A1 (enExample) |
| BR (1) | BRPI1011049A2 (enExample) |
| CA (1) | CA2762527A1 (enExample) |
| IL (1) | IL216420A0 (enExample) |
| MX (1) | MX2011012263A (enExample) |
| NZ (2) | NZ619076A (enExample) |
| RU (1) | RU2539595C2 (enExample) |
| SG (2) | SG176168A1 (enExample) |
| TW (1) | TW201043620A (enExample) |
| WO (1) | WO2010135360A1 (enExample) |
| ZA (1) | ZA201108657B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2666219C (en) | 2006-10-16 | 2017-02-07 | Bionomics Limited | Novel anxiolytic compounds |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| US8927551B2 (en) | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US9149465B2 (en) | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| US9023848B2 (en) | 2011-03-02 | 2015-05-05 | Bionomics Limited | Small-molecules as therapeutics |
| CN103649086A (zh) | 2011-05-12 | 2014-03-19 | 生态学有限公司 | 制备萘啶的方法 |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| CN110914254A (zh) * | 2017-08-10 | 2020-03-24 | 大正制药株式会社 | 唑类取代的吡啶化合物 |
| US10485790B1 (en) | 2018-09-13 | 2019-11-26 | Syneurx International (Taiwan) Corp. | Salts of cycloserine compounds and applications thereof |
| CA3113823A1 (en) * | 2018-10-15 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof |
| CN110016142B (zh) * | 2019-04-30 | 2021-08-03 | 合肥工业大学 | 一种含嘧啶硼酸结构的硅油及其制备方法 |
| KR20220034739A (ko) | 2019-05-31 | 2022-03-18 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| KR20220030222A (ko) | 2019-05-31 | 2022-03-10 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| EP4043444A1 (en) | 2021-02-11 | 2022-08-17 | Basf Se | Substituted isoxazoline derivatives |
| CN116888101A (zh) * | 2021-02-11 | 2023-10-13 | 巴斯夫欧洲公司 | 取代的异噁唑啉衍生物 |
| JP2024508249A (ja) | 2021-02-11 | 2024-02-26 | ビーエーエスエフ ソシエタス・ヨーロピア | 置換イソオキサゾリン誘導体 |
| IL312330A (en) | 2021-10-25 | 2024-06-01 | Kymera Therapeutics Inc | Tyk2 degraders and uses thereof |
| EP4486740A1 (en) | 2022-03-02 | 2025-01-08 | Basf Se | Substituted isoxazoline derivatives |
| EP4238971A1 (en) | 2022-03-02 | 2023-09-06 | Basf Se | Substituted isoxazoline derivatives |
| EP4342885A1 (en) | 2022-09-20 | 2024-03-27 | Basf Se | N-(3-(aminomethyl)-phenyl)-5-(4-phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-amine derivatives and similar compounds as pesticides |
| CN120152959A (zh) | 2022-09-20 | 2025-06-13 | 巴斯夫欧洲公司 | 作为杀有害生物剂的n-(3-(氨基甲基)-苯基)-5-(4-苯基)-5-(三氟甲基)-4,5-二氢异噁唑-3-胺衍生物及类似化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9505651D0 (en) * | 1995-03-21 | 1995-05-10 | Agrevo Uk Ltd | AgrEvo UK Limited |
| US7662971B2 (en) * | 2002-10-08 | 2010-02-16 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| EP1576127A4 (en) * | 2002-11-14 | 2006-10-25 | Scripps Research Inst | CRYSTAL FORM OF FATTY ACID AMINE HYDROLASE (FAAH) |
| US7807696B2 (en) * | 2003-10-07 | 2010-10-05 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
| FR2866888B1 (fr) * | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
| TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| US20070155747A1 (en) * | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| ITMI20061279A1 (it) * | 2006-06-30 | 2008-01-01 | Consiglio Nazionale Ricerche | Agonisti nicotinici selettivi per il sottotipo recettoriale alfa7,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| WO2009011904A1 (en) * | 2007-07-19 | 2009-01-22 | Renovis, Inc. | Compounds useful as faah modulators and uses thereof |
| KR20100111691A (ko) * | 2007-12-27 | 2010-10-15 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 의학 용도를 위한 5-ｏ-치환 3-ｎ-페닐-1,3,4-옥사디아졸론 |
| CN101970432B (zh) * | 2008-01-25 | 2014-05-28 | 杜邦公司 | 杀真菌杂环化合物 |
-
2010
- 2010-05-17 AR ARP100101710A patent/AR076687A1/es unknown
- 2010-05-18 RU RU2011151635/04A patent/RU2539595C2/ru not_active IP Right Cessation
- 2010-05-18 AU AU2010249674A patent/AU2010249674A1/en not_active Abandoned
- 2010-05-18 SG SG2011085503A patent/SG176168A1/en unknown
- 2010-05-18 TW TW099115796A patent/TW201043620A/zh unknown
- 2010-05-18 NZ NZ619076A patent/NZ619076A/en not_active IP Right Cessation
- 2010-05-18 KR KR1020117030377A patent/KR20120042766A/ko not_active Withdrawn
- 2010-05-18 EP EP10778279.9A patent/EP2432771A4/en not_active Withdrawn
- 2010-05-18 JP JP2012511971A patent/JP2012527467A/ja not_active Ceased
- 2010-05-18 SG SG10201402443PA patent/SG10201402443PA/en unknown
- 2010-05-18 WO PCT/US2010/035309 patent/WO2010135360A1/en not_active Ceased
- 2010-05-18 CN CN201080032435.4A patent/CN102459202B/zh not_active Expired - Fee Related
- 2010-05-18 MX MX2011012263A patent/MX2011012263A/es not_active Application Discontinuation
- 2010-05-18 NZ NZ596585A patent/NZ596585A/en not_active IP Right Cessation
- 2010-05-18 BR BRPI1011049A patent/BRPI1011049A2/pt not_active IP Right Cessation
- 2010-05-18 CA CA2762527A patent/CA2762527A1/en not_active Abandoned
-
2011
- 2011-11-17 IL IL216420A patent/IL216420A0/en unknown
- 2011-11-24 ZA ZA2011/08657A patent/ZA201108657B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012527467A5 (enExample) | ||
| JP2013510885A5 (enExample) | ||
| FI2534153T4 (fi) | 8-fluori-2-{4-[(metyyliamino}metyyli]fenyyli}-1,3,4,5-tetrahydro-6h-atsepino[5,4,3-cd]indol-6-onin suoloja ja polymorfeja | |
| RU2016114866A (ru) | Замещенные аминопиримидиновые соединения и способы их использования | |
| JP2013534248A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2014530866A5 (enExample) | ||
| JP2012513481A5 (enExample) | ||
| JP2014531434A5 (enExample) | ||
| JP2010511626A5 (enExample) | ||
| NZ596585A (en) | Isoxazolines as inhibitors of fatty acid amide hydrolase | |
| JP2012530137A5 (enExample) | ||
| JP2014521653A5 (enExample) | ||
| JP2017523169A5 (enExample) | ||
| JP2019504898A5 (enExample) | ||
| JP2014508753A5 (enExample) | ||
| JP2019055988A5 (ja) | 治療用化合物および医薬組成物 | |
| JP2013523897A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2017510610A5 (enExample) | ||
| JP2010509366A5 (enExample) | ||
| JP2012072150A5 (enExample) | ||
| JP2010501584A5 (enExample) | ||
| JP2018533593A5 (enExample) | ||
| JP2013512903A5 (enExample) |